Novartis Pressures Generics Makers Over Exforge ANDA

Law360, New York (May 15, 2012, 4:40 PM EDT) -- Swiss drugmaker Novartis International AG on Monday launched separate patent infringement suits against India-based Lupin Pharmaceuticals Inc. and Torrent Pharmaceuticals Ltd. over their bids to manufacture generic versions of the blood pressure drug Exforge HCT. 

In two complaints filed in Delaware federal court, Novartis claims that Lupin, Torrent and their affiliates infringed Novartis' patent for Exforge by filing abbreviated new drug applications with the U.S. Food and Drug Administration before the expiration of the drug's patent, which is listed under the generic name valsartan. 

"On information and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.